That Australian research is among the best in the world, Yet there is a market failure at the heart of Australian biotech market
Is a fund focused on early stage therapeutics, investing in projects from discovery through preclinical proof of concept and IND enabling studies. We invest in small molecule therapeutics, biologics, and cell and gene therapies for indications with significant unmet need.
By investing in projects from inception through to pre-IPO, we intend to facilitate the continuity of capital from Australian academia to venture financing and through Australian capital markets.
Deal Flow
Capitalise on SYNthesis’ inside look into partner project pipelines to source cutting edge,
Best/First in class therapeutics targeting areas of high value clinical unmet need
Invest in early stage therapeutics
- Discovery thru early clinical development
- Investing in seed, A, and pre-IPO financings
Actively manage our portfolio companies
- Integrate investees into SYNthesis’ vexisting management and R&D operations
- Realise economies of scale by leveraging the SYNthesis Group’s existing resources
Pursue exits across the development spectrum
- We have expertise in generating successful exits in early stage assets
- Aim for liquidity through partnerships, M&A’s and public listings
Our investments are divided according to stage of development, where we intend to deploy:
up to A$1M into early stage projects (discovery through lead optimisation)
A$3-5M into medium stage projects (establishing preclinical proof of concept)
up to A$5M into late preclinical/ early clinical programs.
We are solely focused on therapeutics, but are agnostic with regard to modality and indication.
with leading Australian research institutes, and are able to leverage the skills and resources of the SYNthesis Group in early stage drug development in order to reach value inflection points quickly and economically.
Leave a message and we'll get back you